Fundraising Fox

Neuron23

South San Francisco, US · Founded 2018 · 29 employees on LinkedIn · 11 known investors

Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease. It aims to match patient subsets defined by genetic drivers with targeted therapies for conditions such as Parkinson's and Alzheimer's.

Founders & leadership

NSNancy Stagliano
Nancy StaglianoinChief Executive Officer and Chair of the Board

Investors · 11

Also in the syndicate · 3

Perceptive AdvisorsSoftBank Vision Fund 2leadSurveyor Capital

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Frequently asked questions

What does Neuron23 do?
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease. It aims to match patient subsets defined by genetic drivers with targeted therapies for conditions such as Parkinson's and Alzheimer's.
Who are Neuron23's investors?
Neuron23's investors include Kleiner Perkins, SoftBank Group, SoftBank Vision Fund, Westlake Village BioPartners, ACORN BIOVENTURES, Cowen Healthcare Investments, HBM Partners, REDMILE.
Where is Neuron23 headquartered?
Neuron23 is headquartered in South San Francisco, US.